OncologyTube Professional - Patients Click Here
331,167 video views
Loading........
Description: Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the clinical trials with results being released soon for the treatment of low grade lymphoma. Trials...
01:29
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the clinical trials with results being released soon for the treatment of low grade lymphoma. Trials include several drugs being combined with lenalidomide, as well as checkpoint inhibitors. Speaking ...
by:VJHemOnc | 50 views
04:03
Hyperprogressiv​e disease is a new phenomenon observed in patients treated with anti-PD-1/PD-L1 immunotherapy, characterized by accelerated tumor growth. Interestingly, hyperprogressiv​e disease can occur not just in patients with non-small cell lung cancer, but also in patients with head and neck cancer. Benjamin Besse, MD, PhD from the Institute Gu...
by:VJHemOnc | 24 views
01:38
The key findings of the anaplastic lymphoma kinase-positive non-small cell lung cancer (ALEX) study (NCT02075840) has established alectinib as a key treatment compared with crizotinib. In this talk, Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland, discusses the implic...
by:VJHemOnc | 38 views
02:27
Benjamin Besse, MD, PhD from the Institute Gustave Roussy, Villejuif, France, discusses the outcomes of the recent phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer (NCT02411591). Speaking at the 2018 European Lung Cancer Congress (ELC...
by:VJHemOnc | 34 views
01:51
The 2017 American Society of Hematology (ASH) Annual Meeting, in Atlanta, GA, was an exciting event with results from multiple clinical trials being presented. Here, Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promising results from combining...
by:VJHemOnc | 46 views
02:14
Thrombotic microangiopathy (TMA) is a rare complication that may arise post-transplant in patients, however, incidence of TMA has increased in recent years with no clear reason. Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Enri...
by:VJHemOnc | 18 views
01:07
The complications in blood and marrow transplantation can be serious with rapid onset, therefore ideal donor matching is crucial in minimizing complications. In this talk, Enric Carreras, MD, PhD, from the Hospital Clinic of Barcelona, Barcelona, Spain, outlines the process of donor selection for bl...
by:VJHemOnc | 10 views
03:01
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, discusses the key reasons why EBMT 2018 has been a success. Mohamad talks about the attention that the latest tr...
by:VJHemOnc | 9 views
02:38
There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although previously, treatment was limited for refractory conditions. In this talk, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, alludes to the...
by:VJHemOnc | 16 views
02:21
The therapeutic landscape of Hodgkin lymphoma has improved considerably over the past 50 years, with patient outcomes improving due to accurate diagnoses. Here, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, raises the issue that not all patients respond in the same way to therapy. Speaking from the 2018 European Society for Bl...
by:VJHemOnc | 19 views

About VJHemOnc
Description: The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Links
Channel Url:

Website:


Social Links: